Oruka Therapeutics Reports Q4 Loss and Cash Position
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy ORKA?
Source: seekingalpha
- Earnings Report: Oruka Therapeutics reported a GAAP EPS of -$0.45 for Q4 2025, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, Oruka held $479.6 million in cash, cash equivalents, and marketable securities, providing a solid financial foundation for future research and operational activities.
- Operating Cash Flow: The net cash used in operating activities for Q4 2025 was $22.6 million, a significant increase from $18.8 million in Q4 2024, reflecting rising funding needs as the company expands its operations.
- Annual Comparison: Total net cash used for the full year 2025 reached $88.2 million, up from $57.8 million in 2024, indicating a substantial increase in cash burn as the company scales its operations and invests in growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORKA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORKA
Wall Street analysts forecast ORKA stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.480
Low
40.00
Averages
51.67
High
75.00
Current: 44.480
Low
40.00
Averages
51.67
High
75.00
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
Experts Reveal Top Stock Picks with Doubling Potential
- Stock Potential Recommendations: Experts have revealed five stocks with doubling potential, with one being highlighted by Director of Research Sheraz Mian as superior, indicating its unique market advantage.
- Historical Performance Comparison: While not all recommended stocks are guaranteed winners, this stock is expected to significantly outperform earlier recommendations like Hims & Hers Health, which surged by +209%, drawing investor interest.
- Access to Latest Recommendations: Zacks Investment Research offers the latest seven best stock picks, allowing investors to download this report for free to uncover investment opportunities for the next 30 days.
- Market Insights: The article underscores the author's views and analyses, which may not necessarily reflect those of Nasdaq, Inc., yet provide valuable market insights for investors.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
Oruka Therapeutics Shares Hit 52-Week High Following Data Release Acceleration
- Data Release Acceleration: Oruka Therapeutics announced an accelerated release of EVERLAST-A 16-week data due to rapid patient enrollment, now expected in Q2 2026, which is earlier than the previously anticipated second half of 2026, indicating significant progress in treating moderate-to-severe plaque psoriasis.
- Clinical Trial Advancements: The EVERLAST-B trial commenced in December 2025 to evaluate three different doses of ORKA-001, with data expected in 2027, which will support the initiation of a phase 3 program, further advancing the company's product pipeline.
- Strong Financial Position: As of December 31, 2025, Oruka reported $479.6 million in cash and cash equivalents, ensuring sufficient funding for future clinical trials and enhancing investor confidence in the company's growth prospects.
- Robust Stock Performance: Since September 18, 2025, Oruka's stock price surged from $16.56 to $39.07, reflecting a 22.23% increase, showcasing market optimism regarding the company's future developments.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
Experts Reveal Top Stock Picks with Doubling Potential
- Stock Potential Recommendations: Experts have revealed five stocks with doubling potential, with one being highlighted by Director of Research Sheraz Mian as superior, indicating its unique market advantage.
- Historical Performance Comparison: While not all recommended stocks are guaranteed winners, this stock is expected to significantly outperform earlier recommendations like Hims & Hers Health, which surged by +209%, drawing investor interest.
- Access to Latest Recommendations: Zacks Investment Research offers the latest seven best stock picks, allowing investors to download this report for free to uncover investment opportunities for the next 30 days.
- Market Insights: The article underscores the author's views and analyses, which may not necessarily reflect those of Nasdaq, Inc., yet provide valuable market insights for investors.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
Oruka Therapeutics Shares Hit 52-Week High Following Data Release Acceleration
- Data Release Acceleration: Oruka Therapeutics announced an accelerated release of EVERLAST-A 16-week data due to rapid patient enrollment, now expected in Q2 2026, which is earlier than the previously anticipated second half of 2026, indicating significant progress in treating moderate-to-severe plaque psoriasis.
- Clinical Trial Advancements: The EVERLAST-B trial commenced in December 2025 to evaluate three different doses of ORKA-001, with data expected in 2027, which will support the initiation of a phase 3 program, further advancing the company's product pipeline.
- Strong Financial Position: As of December 31, 2025, Oruka reported $479.6 million in cash and cash equivalents, ensuring sufficient funding for future clinical trials and enhancing investor confidence in the company's growth prospects.
- Robust Stock Performance: Since September 18, 2025, Oruka's stock price surged from $16.56 to $39.07, reflecting a 22.23% increase, showcasing market optimism regarding the company's future developments.
See More
